Analyst Research
| Report Title | Price |
|---|---|
|
Trading Report for (PFE). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Takeda Pharmaceutical Company Limited To Stop Selling 13 Pfizer, Inc. Drugs In Japan-Reuters
Reuters reported that Takeda Pharmaceutical Company Limited will stop distributing 13 Pfizer, Inc. drugs it now sells in Japan at the end of this year and Pfizer itself will begin selling them from 2013. The 13 drugs include antibiotic Minomycin, anticancer agents Torisel and Mylotarg, and depression treatment Amoxan. The list did not include Viagra. Takeda will continue to distribute Prevenar, a pneumococcus vaccine for children, and the haemophilia B drug BeneFIX. It also said it and Pfizer will continue to work together on the arthritis drug Enbrel.
Latest Developments for Pfizer Inc
- Pfizer Inc Lowers FY 2013 Guidance
- European Regulators Reject Pfizer Inc's Arthritis Drug-Reuters
- Pfizer IncPfizer’s Palbociclib (PD-0332991) Receives Food And Drug Administration Breakthrough Therapy Designation For Potential Treatment Of Patients With Breast Cancer
- Pfizer Inc, Novartis AG And Abbott Laboratories Weigh Bids For Brazil's Ache Laboratorios Farmaceuticos-Reuters
Latest Key Developments in Pharmaceuticals
- AmerisourceBergen Corp Reaffirms FY 2013 EPS Gudiance-Conference Call
- Immunotec Inc Announces New CEO
- Novo Nordisk A/S Reports Positive Results from First Phase 3 Trial with Long-Acting Factor IX for Treatment of Haemophilia B
- Sanofi SA Announces Positive Results on Pivotal Study of Inhibitor in Myelofibrosis-DJ
- Share this
- Link this
- Digg this
Follow Reuters